跳至主要内容
临床试验/NCT02203357
NCT02203357已完成4 期

A Randomized, Opened, Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Young Adults

Peking University2 个研究点 分布在 1 个国家目标入组 353 人开始时间: 2014年3月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
353
试验地点
2
主要终点
Immunogenicity of Hepatitis B Vaccine With Different Doses and Schedules in Healthy Young Adults

研究概览

简要总结

The objective of this study is to evaluate the immunogenicity and Anti-HBV antibody persistence of hepatitis B vaccine with different doses and schedules. Hepatitis B vaccine with the regimens of 20μg, 0-1-6 mon and 60μg,0-1 or 0-2 mon will be administered to young adults, and the comparative immunogenicity among the three groups will be measured at 1 mon post-a series vaccination, 1- and 2-year after the first dose of the regimen. Furthermore, the safety of hepatitis B vaccine with different doses and schedules will also be evaluated.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 25 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy subjects aged between 16 and 25 as established by medical history and clinical examination
  • Written informed consent will be obtained from each subject before the serum screening of HBV markers
  • Seronegative for HBsAg, anti-HBs antibody, anti-HBc antibody
  • Have never been immunized with HBV vaccine before

排除标准

  • Subject has a medical history of allergic to any ingredient of vaccine
  • Family history of seizures or progressive neurological disease
  • Autoimmune disease or immunodeficiency
  • Women with pregnant
  • Bleeding disorder diagnosed by a doctor
  • Chronic diseases: hepatitis, tumor, tuberculosis,et.al
  • Any prior administration of immunoglobulins or blood products in the last 3 mon before recruitment
  • Subjects had a medical history of serious adverse reactions to vaccines

研究组 & 干预措施

60μg, 0-1

Experimental

112 young adults were administered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.

干预措施: Hepatitis B vaccine (Biological)

20μg, 0-1-6

Active Comparator

117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.

干预措施: Hepatitis B vaccine (Biological)

60μg, 0-2

Experimental

125 young adults were administered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.

干预措施: Hepatitis B vaccine (Biological)

结局指标

主要结局

Immunogenicity of Hepatitis B Vaccine With Different Doses and Schedules in Healthy Young Adults

时间窗: one month after a series vaccination of the regimen

The measurements of anti-HBs antibodies were determined quantitatively by CMIA using the Architect i2000SR analyzer (Abbott, Chicago, IL, USA). The accepted protective serum anti-HBs level was ≥10 mIU/ml. Anti-HBs≥10 and \< 100 mIU/ml were considered low response, and anti-HBs concentrations ≥100 but \< 1000 mIU/ml were middle or moderate response, and hyper or high response was associated with an anti-HBs level ≥1000 mIU/ml. The GMCs of anti-HBs antibody will be compared among the three vaccine groups.

次要结局

  • Immunogenicity of Hepatitis B Vaccine With Different Doses and Schedules in Healthy Young Adults(2-year after the first dose of the regimens)

研究者

发起方
Peking University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xueen Liu

Dr.

Peking University

研究点 (2)

Loading locations...

相似试验